BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-876@pharmaconomics
DTSTAMP:20260707T033837Z
DTSTART;VALUE=DATE:20260420
DTEND;VALUE=DATE:20260421
SUMMARY:ELTX Phase 2 — ELI-002 7P
DESCRIPTION:Phase 2 trial results for ELI-002 7P in adjuvant mKRAS-driven pancreatic ductal adenocarcinoma are due Apr 20\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1601485/000160148526000046/a8k-deckconferencecallfi.htm\n\nTrack it: https://pharmaconomics.com/e/876
URL:https://pharmaconomics.com/e/876
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:ELTX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR